NEW YORK, June 2, 2017 /PRNewswire/ --
Stock-Callers.com today has lined up for assessment the following Medical
On Thursday, shares in North Chicago, Illinois headquartered Abbott Laboratories rose 0.96%, ending the day at $46.10. The stock recorded a trading volume of 7.39 million shares, which was above its three months average volume of 6.52 million shares. The Company's shares have advanced 5.73% in the last one month, 0.90% over the previous three months, and 20.02% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.72% and 9.46%, respectively. Moreover, shares of Abbott Labs, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 70.93.
On May 09th, 2017, Abbott Labs announced CE Mark of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, developed to make it easier for physicians to more effectively treat atrial fibrillation, a condition in which the upper chambers of the heart beat too fast. When integrated with the Company's EnSite Precision™ cardiac mapping system, physicians are able to utilize dual impedance and magnetic technologies to help more precisely model the heart. ABT complete research report is just a click away and free at: http://stock-callers.com/registration/?symbol=ABT
Shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. ended the day 2.15% higher at $27.61. A total volume of 13.26 million shares was traded, which was above their three months average volume of 6.69 million shares. In the last month and the previous three months, the stock has gained 3.84% and 10.44%, respectively. Additionally, the Company's shares have advanced 27.65% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.83% and 16.18%, respectively. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 68.87.
On May 24th, 2017, Boston Scientific announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma study evaluating patients treated with the Alair™ System. The data, presented at the American Thoracic Society International Conference in Washington, D.C., demonstrate that BT reduces complications in adult patients with severe persistent asthma. The complimentary report on BSX can be downloaded at: http://stock-callers.com/registration/?symbol=BSX
At the close of trading on Thursday, shares in Dublin, Ireland headquartered Medtronic PLC finished 2.14% higher at $86.08. A total volume of 7.53 million shares was traded, which was above their three months average volume of 4.30 million shares. The stock has advanced 1.57% in the last one month, 4.99% over the previous three months, and 20.85% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 4.70% and 6.80%, respectively. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 65.74.
On May 31st, 2017, Medtronic announced that it recently launched PRODIGY, a 1,650-patient global study, to identify individuals at high risk for opioid induced respiratory depression, a form of respiratory compromise. It is the first study to assess the clinical and economic benefits derived from the use of pulse oximetry (a device that measures oxygen saturation and pulse rate) and capnography (a device that measures carbon dioxide in exhaled air and respiration rate) in patients receiving opioid medication on hospital general care floors. Sign up for your complimentary research report on MDT at: http://stock-callers.com/registration/?symbol=MDT
St. Paul, Minnesota headquartered EnteroMedics Inc.'s shares recorded a trading volume of 754,302 shares at the end of yesterday's session. The stock closed the day 0.19% lower at $5.25. The Company's shares have advanced 25.90% in the past month and 162.50% on an YTD basis. The stock is trading above its 50-day moving average by 3.10%. Additionally, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 55.43.
On May 31st, 2017, EnteroMedics announced that AMITA Health Adventist Medical Center Bolingbrook in Bolingbrook, Illinois successfully completed its first implant of the Company's vBloc® Neurometabolic Therapy. The procedure was performed approximately three months ago by Vafa Shayani, M.D., a bariatric surgeon at the AMITA Health Bariatric & Weight Loss Center, and the patient already has lost about 30 pounds. Get free access to your research report on ETRM at: http://stock-callers.com/registration/?symbol=ETRM
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All